Last reviewed · How we verify
Age and Response to Flu Vaccines
The study will be designed as a prospective surveillance of the immune response to seasonal influenza vaccination in 240 healthy children and adults ages 9 and over. Study duration will be 5 years, with a participant duration of 6 months. Subjects will receive a quadrivalent inactivated influenza vaccine, at a dose of not less than 15 ug of hemagglutinin (HA), by intramuscular injection in open label fashion on day 0. Blood draws will occur at baseline, day 7, 28 and 90. The primary objective of this study is to evaluate the relationship between first influenza A virus exposure (inferred by age), vaccine history, and baseline serum antibody response to seasonal influenza vaccine in healthy adults and children.
Details
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
|---|---|
| Phase | PHASE4 |
| Status | COMPLETED |
| Enrolment | 152 |
| Start date | Thu Dec 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Apr 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Influenza
- Influenza Immunisation
Interventions
- Influenza Virus Quadrivalent Inactivated Vaccine
- Influenza Virus Quadrivalent Inactivated Vaccine
Countries
United States